Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy
Cell · 2024-11 · 187 (24) · 6966-6980.e23
DOI: 10.1016/j.cell.2024.09.043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2024-11. Verfasst von Yufei Xiang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Center of Protein Engineering and Therapeutics, Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, …. Hauptthemen laut MEDLINE: Single-Domain Antibodies, Epitopes, SARS-CoV-2, Antiviral Agents. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIGMS NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center of Protein Engineering and Therapeutics, Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Division of Structural Biology, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Biomedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Department of Pharmacology, Case Western Reserve University, Cleveland, OH, USA.
- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic…
Förderung
- NIAID NIH HHS
- NIGMS NIH HHS
- NCATS NIH HHS
- NHLBI NIH HHS
- National Institute of Allergy and Infectious Diseases
- Icahn School of Medicine at Mount Sinai
- National Heart Lung and Blood Institute
- National Center for Advancing Translational Sciences
Zitieren
APA
Xiang, Y., Xu, J., McGovern, B. L., Ranzenigo, A., Huang, W., Sang, Z., Shen, J., Diaz-Tapia, R., Pham, N. D., Teunissen, A. J. P., Rodriguez, M. L., Benjamin, J., Taylor, D. J., van Leent, M. M. T., White, K. M., García-Sastre, A., Zhang, P., & Shi, Y. (2024). Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy. Cell, 187(24), 6966-6980.e23. https://doi.org/10.1016/j.cell.2024.09.043
Vancouver
Xiang Y, Xu J, McGovern BL, Ranzenigo A, Huang W, Sang Z, et al. Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy. Cell. 2024;187(24):6966-6980.e23. doi:10.1016/j.cell.2024.09.043
BibTeX
@article{Xiang2024,
author = {Xiang, Yufei and Xu, Jialu and McGovern, Briana L and Ranzenigo, Anna and Huang, Wei and Sang, Zhe and Shen, Juan and Diaz-Tapia, Randy and Pham, Ngoc Dung and Teunissen, Abraham J P and Rodriguez, M Luis and Benjamin, Jared and Taylor, Derek J and van Leent, Mandy M T and White, Kris M and García-Sastre, Adolfo and Zhang, Peijun and Shi, Yi},
title = {Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy},
journal = {Cell},
year = {2024},
volume = {187},
number = {24},
pages = {6966--6980.e23},
doi = {10.1016/j.cell.2024.09.043}
}
EUVIMED